Dr. Amy Sehnert is the Chief Medical Officer of Thryv Therapeutics. A pediatric cardiologist and physician-scientist, Dr. Sehnert began her academic career at UCSF and Stanford University, before gaining over 20 years of experience as an executive clinical leader in developing and launching precision diagnostics and therapeutics for patients.

Prior to joining Thryv, Dr. Sehnert was Vice President and Global Program Lead at Bristol Myers Squibb (BMS), where she led cardiovascular transition assets targeting cardiomyopathies and heart failure. She joined BMS through the acquisition of MyoKardia, Inc., where she served as Vice President of Clinical Science. In this role, she led the pivotal Phase 3 EXPLORER-HCM trial of mavacamten, contributing to the global regulatory filings that resulted in the approval of Camzyos® (a first-in-class treatment for symptomatic obstructive hypertrophic cardiomyopathy) in 45 countries, starting with the US FDA in April 2022. She also spearheaded Phase 2, 3, and long-term extension studies of mavacamten, helping to integrate it into practice guidelines in the US and EU.

Dr. Sehnert has also made significant contributions in genomic diagnostics, working with companies such as CardioDx, Verinata Health, Illumina, and GRAIL. Her work in noninvasive prenatal testing (NIPT) and oncology screening through cell-free DNA sequencing technologies has had a lasting impact on these fields. Throughout her career, she has co-authored over 60 publications in top-tier journals.

In 2022, Dr. Sehnert was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco.

Dr. Sehnert holds a bachelor's degree in mechanical engineering and a Doctor of Medicine from the University of Minnesota, where she currently serves on the Medical School Alumni Board. She completed her residency in Pediatrics at the University of Colorado/The Children’s Hospital and fellowship in Pediatric Cardiology at UCSF, where she was a fellow in the Pediatric Scientist Training Program. She later served as an assistant professor and principal investigator of NIH-K08, American Heart Association young investigator, and institution-based grants.